Vimarsana
Biggest News Aggregation in the World

Page 2 - Patrick Bursey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Bursey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Bursey Today - Breaking & Trending Today

Cidara Therapeutics to Host Research and Development Day - Vimarsana News

Cidara Therapeutics to Host Research and Development Day

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Topical Treatment for EB Recommended for Approval in the EU - Vimarsana News

Topical Treatment for EB Recommended for Approval in the EU

In February, the FDA declined to approve the company's new drug application as it was presented and asked the company to submit additional evidence of effectiveness for epidermolysis bullosa (EB).

Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB - Vimarsana News

Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Cidara Therapeutics Provides Corporate Update and Reports - Vimarsana News

Cidara Therapeutics Provides Corporate Update and Reports

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics...

Mundipharma and Cidara Therapeutics, Inc.: Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis - Vimarsana News

Mundipharma and Cidara Therapeutics, Inc.: Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis

For Trade and Medical Media Only Rezafungin is a next-generation once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis